Compare Eli Lilly And Co (LLY) vs Union Pacific Corporation (UNP) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Union Pacific (UNP) trades at $296.00, down 1.91% amid mixed technical signals. The stock shows strong fundamentals with 29.2% net margins and 40.69% ROE, while Q1 2026 earnings beat expectations. Analysts maintain a bullish consensus with a $311.07 price target. Recent news highlights the Norfolk Southern merger progress and upcoming Q2 earnings, with institutional buying supporting positive sentiment despite regulatory and legal overhangs.

Outlook remains positive given earnings momentum and operational efficiency, but risks include merger regulatory scrutiny, pending class action litigation, and cyclical freight demand. The stock offers value near consensus targets with dividend growth, though investors should weigh execution risks against solid profitability trends.